The DASbox® Mini Bioreactor System as a tool for process development and stem-cell derived exosome production in standardized culture conditions

Stem cell-derived exosomes have become a key area of interest for cell-free therapeutic tools due to their strong diagnostic and therapeutic potential in various diseases. They offer several advantages compared to cell-based approaches – for example, they have exceptional stability and biocompatibility, and can be delivered to target tissue easier than whole cells.

However, the use of exosomes as a cell-free therapeutic tool requires the production of clinically relevant amounts of high-quality vesicles. This requires an efficient manufacturing process that must be standardized, reproducible and scalable. Stirred-tank bioreactors can help to achieve this challenge, as they provide a controlled environment that can facilitate the standardized expansion of high-yield viable cells and enhance the reproducible production of extracellular vesicles.

In this application note, explore the suitability of BioBLU® 0.3c Single-Use Bioreactors – controlled by a DASbox® Mini Bioreactor System – in the production of exosomes secreted by human adipose-derived stem cells. This fully controlled system allows an expansion of high yield of viable cells and optimizes the production of high-quality extracellular vesicles in standardized culture conditions.

This content was supplied by Eppendorf.

This article is part of the RegMedNet Spotlight on acellular regenerative medicine. Click here to view the full feature >>>